Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Physiologically Relevant Cell Culture Handbook

April 3, 2014 5:00 pm | Product Releases | Comments

AMS Biotechnology (AMSBIO) has produced an extensive 48-page handbook for research scientists looking to culture cells in more physiologically relevant environments.

Astellas, Medivation Submit Amended MAA for New Xtandi Use

April 3, 2014 1:22 pm | News | Comments

Astellas Pharma and Medivation announced the submission of a variation to amend the European Marketing Authorization Application for Xtandi (enzalutamide) capsules for a new indication in the treatment of adult men with metastatic castration-resistant prostate cancer. Read more...


Study Helps Unravel the Tangled Origin of ALS

April 3, 2014 1:14 pm | News | Comments

By studying nerve cells that originated in patients with a severe neurological disease, a University of Wisconsin-Madison researcher has pinpointed an error in protein formation that could be the root of amyotrophic lateral sclerosis. Read more...


Glenmark's Chronic Inflammatory Disease Drug Enters Human Trials

April 3, 2014 1:00 pm | News | Comments

Glenmark Pharmaceuticals announced that its Novel Chemical Entity (NCE) GRC 27864, a potent, selective, and orally bioavailable inhibitor of Microsomal Prostaglandin E synthase-1 (mPGES-1), is entering Phase 1human trials. Read more...   


FDA Accepts Omeros IND App for TMA Treatment

April 3, 2014 12:45 pm | News | Comments

Omeros Corp. announced that its Investigational New Drug (IND) Application to evaluate OMS721 for the inhibition of complement mediated thrombotic microangiopathies (TMAs) has been cleared by the U.S. Food and Drug Administration (FDA). Read more...


BioDelivery Sciences Opens Phase 3 Trial of Diabetic Neuropathy Gel

April 3, 2014 12:37 pm | News | Comments

BioDelivery Sciences International Inc. announced the enrollment of the first patient in the RHAPSODY Study, a Phase 3 clinical trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy. Read more...       


Fertility Drugs Do Not Increase Breast Cancer Risk

April 3, 2014 12:26 pm | News | Comments

Women who took clomiphene citrate or gonadotropins as a part of fertility treatment did not experience an increased risk for breast cancer over 30 years of follow-up, compared with women who were not treated with these medications, according to a study. Read more...


Gilead Hep C Combo Hits Primary Endpoint in Japan

April 3, 2014 11:10 am | News | Comments

Gilead Sciences announced top-line results from a Phase 3 clinical trial in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection. Read more...


EU Committee Backs Orphan Status for Alnylam RNAi Drug

April 3, 2014 11:02 am | News | Comments

Alnylam Pharmaceuticals announced that the European Medicines Agency Committee for Orphan Medicinal Products has adopted a positive opinion recommending ALN-TTRsc for designation as an orphan medicinal product for the treatment of transthyretin-mediated amyloidosis (ATTR). Read more...


Ketamine Can Treat Severe Depression

April 3, 2014 10:33 am | News | Comments

New research confirmed that ketamine has a rapid antidepressant effect in some patients with severe depression who have not responded to other treatments. Read more...                        


How Personalized Medicine Works: Bioinformaticians to the Rescue

April 3, 2014 10:23 am | Videos | Comments

In our third video, Rob Fee is back to discuss how informatics can help to overcome one of the biggest challenges in personalized medicine: organizing and examining the mountains of data that are generated during the gene sequencing process. Rob's advice? Find a!


Takeda Gets JPMA Suspension Over Candesartan Marketing

April 3, 2014 3:20 am | News | Comments

Takeda Pharmaceutical Co. Ltd. received notice of sanctions imposed by the Japan Pharmaceutical Manufacturers Association (JPMA) for promotional activities regarding Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J). Read more...


Daiichi Sankyo, UCSF Partner on Neurodegenerative Drugs

April 2, 2014 9:19 pm | News | Comments

Daiichi Sankyo and UCSF announced that they have established a drug discovery collaboration focused on developing novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases. Read more...           


Traceable Tissue Storage Solution

April 2, 2014 4:18 pm | Product Releases | Comments

Micronic has launched a new externally threaded 3.00 ml tube that provides a fully traceable storage solution for tissue samples. Read more...


Cognition Therapeutics Receives U.S. Patent for Alzheimer's Drug

April 2, 2014 3:25 pm | News | Comments

Patent describes the discovery of several candidate drug molecules which can stop the effects of the brain protein that appears to play a major role in development of Alzheimer's disease. Read more...          



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.